Evidence map›Paper›PMID 26617280›Full record

ReviewJournal of neurochemistry2016

Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.

Trevor Tyson, Jennifer A Steiner, Patrik Brundin

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Journal of neurochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04266457 (Establishing Alpha-synuclein Real Time - Quaking Induced Conversion), which is not on this map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04266457 withdrawnnot on this mapstarted 2021, after this paper: background citation

Establishing Alpha-synuclein Real Time - Quaking Induced Conversion (RT-QuIC) Assay as a Diagnostic Technique in Rapid Eye Movement (REM) Sleep Behaviour Disorder (RBD)

TypeobservationalSponsorUniversity of EdinburghRan2021 to 2022Enrolled0ConditionsSleep Disorder Rem Sleep Behavior, Parkinson's Disease, Lewy BodyArmsNo Intervention
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 98 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Emerging Nanotechnology for Treatment of Alzheimer's and Parkinson's Disease.Frontiers in bioengineering and biotechnology · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Trevor TysonCenter for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, Michigan, USA.
Jennifer A SteinerCenter for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, Michigan, USA.
Patrik BrundinCenter for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, Michigan, USA. patrik.brundin@vai.org.
Van Andel Institute · US

Funding

Does Microglial Activation Influence Propagation of Alpha-synuclein PathologyR21NS093993 · NINDS · VAN ANDEL RESEARCH INSTITUTE · PI BRUNDIN, PATRIK · 2016 to 2017
$523k
NINDS NIH HHS R21 NS093993
6 · The paper itself

Abstract

Parkinson's disease is a progressive neurological disorder that is characterized by the formation of intracellular protein inclusion bodies composed primarily of a misfolded and aggregated form of the protein α-synuclein. There is growing evidence that supports the prion-like hypothesis of α-synuclein progression. This hypothesis postulates that α-synuclein is a prion-like pathological agent and is responsible for the progression of Parkinson pathology in the brain. Potential misfolding or aggregation of α-synuclein that might occur in the peripheral nervous system as a result of some insult, environmental or genetic (or more likely a combination of both) that might spread into the midbrain, eventually causing degeneration of the neurons in the substantia nigra. As the disease progresses further, it is likely that α-synuclein pathology continues to spread throughout the brain, including the cortex, leading to deterioration of cognition and higher brain functions. While it is unknown why α-synuclein initially misfolds and aggregates, a great deal has been learned about how the cell handles aberrant α-synuclein assemblies. In this review, we focus on these mechanisms and discuss them in an attempt to define the role that they might play in the propagation of misfolded α-synuclein from cell-to-cell. The prion-like hypothesis of α-synuclein pathology suggests a method for the transmission of misfolded α-synuclein from one neuron to another. This hypothesis postulates that misfolded α-synuclein becomes aggregation prone and when released and taken up by neighboring cells, seeds further misfolding and aggregation. In this review we examine the cellular mechanisms that are involved in the processing of α-synuclein and how these may contribute to the prion-like propagation of α-synuclein pathology. This article is part of a special issue on Parkinson disease.

Indexed as

alpha-SynucleinAnimalsHumansParkinson DiseasePrion DiseasesPrion ProteinsProtein AggregatesProtein Transportalpha-SynucleinPrion ProteinsProtein AggregatesautophagyexocytosishomeostasisParkinson's diseaseprionα-synuclein

Identifiers

PMID26617280
PMCPMC4958606
OpenAlexW2187596915

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.